CPPG
CPPG structure
|
Common Name | CPPG | ||
|---|---|---|---|---|
| CAS Number | 183364-82-1 | Molecular Weight | 271.20600 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C11H14NO5P | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Symbol |
GHS07 |
Signal Word | Warning | |
|
Examination of VLC-PUFA-deficient photoreceptor terminals.
Invest. Ophthalmol. Vis. Sci. 55(7) , 4063-72, (2014) Juvenile-onset autosomal dominant Stargardt-like macular dystrophy (STGD3) is caused by mutations in ELOVL4 (elongation of very long fatty acids-4), an elongase necessary for the biosynthesis of very long chain fatty acids (VLC-FAs ≥ C26). Photoreceptors are ... |
|
|
Neuroprotective potential of the group III mGlu receptor agonist ACPT-I in animal models of ischemic stroke: In vitro and in vivo studies.
Neuropharmacology 102 , 276-94, (2016) In the present study, we investigated the effect of ACPT-I [(1S, 3R,4S)-1-aminocyclopentane-1,2,4-tricarboxylic acid], a blood-brain-barrier permeable agonist of group III mGlu receptor, against oxygen-glucose deprivation (OGD)-evoked neuronal cell death in p... |
|
|
Distinct effects of mGlu4 receptor positive allosteric modulators at corticostriatal vs. striatopallidal synapses may differentially contribute to their antiparkinsonian action.
Neuropharmacology 85 , 166-77, (2014) Metabotropic glutamate 4 (mGlu4) receptor is a promising target for the treatment of motor deficits in Parkinson's disease (PD). This is due in part to its localization at key basal ganglia (BG) synapses that become hyperactive in this pathology, particularly... |